Doctor jumping out of his chair next to a large flaming heart
Doctor jumping out of his chair next to a large flaming heart

ACT FAST

Because this is where

ATTR-CM is Headed

If your patient is experiencing HFpEF or other heart disease 
symptoms, ATTR-CM could be an underlying cause.1,2

ATTR-CM is an underdiagnosed, progressive, and fatal 
disease with a median survival of 2.6 to 5.8 years from 
diagnosis. Early detection and identification are critical.2-6

A Progressive,

multisystem disease1,2

Learn what is different about HF caused 
by ATTR-CM, and how you can recognize it.

Recognize

Know the red-flag symptoms

Be on the lookout for red-flag symptoms of ATTR-CM that can prompt additional assessments.

Identify

timely diagnosis is critical2,6

Know the diagnostic assessments that can help identify patients with ATTR‑CM who may already be in your practice.

Diagnose

ATTR=transthyretin-mediated amyloidosis; ATTR‑CM=cardiomyopathy of transthyretin-mediated amyloidosis; HF=heart failure; HFpEF=heart failure with preserved ejection fraction.

References:

  1. Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2016;68(2):161-172. doi:10.1016/j.jacc.2016.03.596
  2. Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. J Am Coll Cardiol. 2023;81(11):1076-1126. doi:10.1016/j.jacc.2022.11.022
  3. Rozenbaum MH, Large S, Bhambri R, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther. 2021;10(1):141-159. doi:10.1007/s40119-021-00219-5
  4. Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140:16-26. doi: 10.1161/CIRCULATIONAHA.118.038169
  5. Kourelis TV, Gertz MA. Improving strategies for the diagnosis of cardiac amyloidosis. Expert Rev Cardiovasc Ther. 2015;13(8):945-961. doi:10.1586/14779072.2015.1069181
  6. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7-e22. doi:10.1161/cir.0000000000000792